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International multicenter trials have the advantage of being able to recruit many patients
within a short period. This is particularly useful for rare diseases. Ideally, conclusions
drawn from the results of a global clinical trial apply to all study centers and countries
involved, potentially expediting drug development and facilitating approval in foreign
markets. However, several challenges must be overcome to ensure optimal trial conduct
and coordinate trial sites working under different regulations and technical and cultural
conditions. Thus, standardizing these trial elements is essential and may include training
courses for the medical and technical staff at the study sites. Considering a rare disease,
such as idiopathic pulmonary ﬁbrosis (IPF), it is the trial sponsor's responsibility to seek
consensus among clinical experts and regulatory agencies about fundamental questions,
including a consistent diagnosis. In cross-cultural studies, it is important to use hard
(objective) efﬁcacy endpoints rather than patient-reported (subjective) measures, such as
quality of life. A quality assurance program should be implemented, including the central
review of diagnostic ﬁndings. Careful safety monitoring and an external independent data
monitoring committee that periodically assesses a study treatment's risk–beneﬁt ratio are
required to protect trial patients from potential harm. Over the past few years, Boehringer
Ingelheim has conducted two large-scale global clinical trials for the treatment of IPF
(INPULSIS™-1 and INPULSIS™-2). These studies have just been completed and, as a result
of careful planning, have successfully complied with the standards and needs of an
international, cross-cultural study.
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Pharmaceutical companies engaged in drug research and devel-
opment (R&D) currently face major and complex challenges.
R&D costs, including trial costs that account for more than half
of the total R&D expenses of research-based drug companies,
have continuously increased over the last decades [1]. Moreover,
regulatory requirements have become more stringent and, in
many countries, companies must provide additional evidence
that their new products offer an efﬁcacy, safety, or economic
advantage over established medicines to justify reimbursement
of treatment costs by third-party payers; yet, there is an
increasing demand for innovative drugs for chronic and complex
diseases.
Clinical trials for the evaluation of new treatments for rare
diseases pose additional problems. Given the small number of
individuals affected, the main challenge of these trials is slow
patient recruitment. In this setting, global trials may be an
appropriate alternative to single center or national clinical trials
as they have the potential to accrue a sufﬁcient number of
patients in a reasonable timeframe. Conducting global clinical
trials is also an attractive strategy to include both developed and
emergingmarket countries simultaneously in drug development.
For global trials to be successful, however, many obstacles must
be overcome.2. The lessons to learn
Boehringer Ingelheim (BI), an international research-based phar-
maceutical company, has gained valuable experience over the
past decade in implementing and conducting global clinical trials
for the development of drugs to treat respiratory diseases.
Examples are the Understanding Potential Long-term Impacts
on Function with Tiotropium (UPLIFT) [2] and Prevention of
Exacerbations with Tiotropium (POET) [3] trials and, more
recently, the TIOtropium Safety and Performance In Respimat
(TIOSPIR) trial [4] of anticholinergic treatment with tiotropium for
chronic obstructive pulmonary disease (COPD). However, in the
ﬁeld of rare lung diseases, there is still concern about whether a
multi-national study would succeed. Taking interferon gamma-
1b (IFN-γ) for idiopathic pulmonary ﬁbrosis (IPF) as an example,
many small trials as well as the GIPF-001, a randomized, double-
blind study of IFN-γ versus placebo in 330 patients with steroid-
resistant IPF [5], had indicated the efﬁcacy of this treatment;
however, these results could not be conﬁrmed in the large-scale
multinational phase III study, INternational study of Survival
outcomes in idiopathic Pulmonary ﬁbrosis with InteRfEron1BI, Boehringer Ingelheim; COPD, chronic obstructive pulmonary
disease; EMA, European Medicines Agency; FDA, Federal Drug
Administration; GCP, Good Clinical Practice; HRCT, high-resolution
computed tomography; ICH, International Conference on Harmo-
nization; IDMC, independent data monitoring committee; IPF, idio-
pathic pulmonary ﬁbrosis; PMDA, Pharmaceuticals and Medical
Devices Agency (Japan); R&D, research and development.gamma-1b (INSPIRE), which included 826 patients with mild-to-
moderate lung function impairment [6].
Recently, global clinical trials conducted concurrently in
multiple countries according to a single protocol have become
increasingly used to recruit many patients in a short period.
The conclusions drawn from the results of the total study
should ideally apply to all participating study centers and
countries, provided that some basic rules and requirements on
good trial conduct are considered. These include, among
others, precise deﬁnition of the target population, compar-
ability of standard care for the patients across the study
regions, the use of appropriate (hard) study endpoints that
are not biased by cultural differences (e.g., use of patient-
reported measures of quality of life or perceived general
health), as well as expert trial management.
If the regions or countries involved in a global trial are
heterogeneous in their ethnic background, this may hamper
the reproducibility and generalizability of the study results.
The following properties make a drug particularly susceptible
to ethnic sensitivity [7]: Nonlinear pharmacokinetics.
 A steep pharmacodynamic dose–response curve for both
efﬁcacy and adverse events and a narrow therapeutic
range. Administration as a pro-drug or extensive metabolism, espe-
cially by enzymes known to exhibit genetic polymorphism. Low bioavailability or high inter-patient variation in
bioavailability. High probability of inappropriate use of the drug or concur-
rent use of multiple medications.
The International Conference on Harmonization (ICH)
E5 guidance published by the Food and Drug Administration
(FDA) gave recommendations for appropriate regulatory and
development strategies to permit clinical data collected in one
region to be used for the support of drug and biologic registra-
tions in another region, while allowing for the inﬂuence of ethnic
factors [7]. It is emphasized that any candidate medicine for
global development should be characterized as ethnically sensi-
tive/insensitive, and, ideally, this should be done during the early
clinical phases of drug development. The ICH-E5 guidance
includes an overview of intrinsic and extrinsic ethnic factors to
be considered. Intrinsic factors are those related to the genetic
and physiologic characteristics of a population, while extrinsic
factors are related to the cultural and environmental character-
istics (Table 1). Smoking, alcohol consumption, food habits, and
stress are factors that share both intrinsic and extrinsic features.3. Challenges to global trials for rare lung
diseases
A global clinical trial for rare diseases, such as IPF, faces addi-
tional, partly unknown challenges. Although evidence-based
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issued [8], many aspects of the disease remain ill deﬁned. An
accurate diagnosis requires the concerted expertise of a multi-Fig. 1 – Collaboration between the sponsor, academia, and
regulatory agencies is the prime determinant of a trial's
success.
Fig. 2 – IPF Advisory Board sponsored




Gender Climate, sun exposure, pollution
Height and bodyweight Culture
Race Socioeconomic factors, education etc.
Genetic polymorphism Medical practice
Organ functions Disease deﬁnition, diagnostic and
therapeutic approach, drug
compliance
Genetic diseases Regulatory practice/GCP
Comorbid conditions Methodology/Endpointsdisciplinary team involving pulmonologists, radiologists, and
pathologists [9], leaving uncertainties about the correct diagnosis
in small centers and about consistency across centers. Moreover,
there are no universally accepted severity grading and prognostic
scoring systems for IPF, no uniform deﬁnition of IPF exacerba-
tions, and no globally accepted standard of care. Since IPF is a
heterogeneous disease, it may be difﬁcult to obtain clinically
representative study populations. As an international company
and a sponsor, BI is fully aware of these difﬁculties, which need
to be properly addressed and managed before study implemen-
tation as well as during the trial. This includes, for example,
leading discussions with clinicians involved in the disease
management from various countries and asking for their opinion
on whether the diagnostic/therapeutic situation is speciﬁc to
their country or to the disease. Sponsors therefore ﬁnd it difﬁcult
to conduct clinical trials based on the latest scientiﬁc develop-
ments and guidelines, and in consensus with clinical experts
and regulatory agencies, such as the FDA, European Medicines
Agency (EMA), and Pharmaceuticals and Medical Devices Agency
(Japan) (PMDA). However, this collaboration is indispensable to
these trials' success (Fig. 1).
Among the obstacles to the clinical trials in rare lung
diseases are the following:byThere is considerable variability in diagnosis and manage-
ment of rare lung diseases. This may translate into
difﬁculties in designing appropriate study protocols and
standardizing all relevant elements of the study, including
well-deﬁned diagnostic, inclusion, and exclusion criteria,
and suitable endpoints. This variability also poses major
challenges to the study's execution. It is often difﬁcult to ﬁnd enough study centers, as few
institutions have both expertise in the treatment of the
respective disease and a reasonable number of patient
referrals. Safety monitoring can be challenging.While planning the global IPF trials, BI sought expert
support through establishing a steering committee (Fig. 2).
Thus, eligibility criteria and endpoints were deﬁned on theBoehringer Ingelheim corporate.
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lating the regulations and requirements as speciﬁed in the
protocol into clinical conduct of the trial across all centers,
countries, and regions represented another major challenge.
For example, to deﬁne general standards for the diagnostic
procedures used in patients with IPF, BI established image
acquisition guidelines for high-resolution computed tomo-
graphy (HRCT) scans and provided all study centers with
appropriate software to transmit the HRCT data for central
review. Quality assurance to minimize diagnostic variability
also included central review of the available lung biopsies.
To achieve high precision and uniformity of lung function
measurements, the same spirometric equipment was used
across all participating centers. Training courses were given
by the vendor to familiarize institutional staff with their
proper use, and a proﬁciency test had to be passed before
the trial's start.
A speciﬁc problem of global trials in rare diseases, includ-
ing IPF, is poor recruitment. Facilities specialized in the
treatment of such diseases are generally attractive candi-
dates for clinical trials. As such, they may not be willing or
capable of participating in another trial because of concurrent
multiple overlapping or competing trials. Reluctance among
potential study centers may also be explained by the high
standards of ICH Good Clinical Practice (GCP) required by both
the sponsor and regulatory authorities (e.g., the FDA, EMA,
and PMDA). Another issue is that local staff experienced in
conducting clinical trials is needed as part of the adminis-
trative structure of the global trial.4. Safety monitoring
Safety monitoring to protect patients from potential serious
side effects of new treatments is a principal responsibility ofFig. 3 – Data ﬂow and decision tree in trials s
Table 2 – Incidence of fatal adverse events in clinical trials
of idiopathic pulmonary ﬁbrosis (IPF) and chronic
obstructive pulmonary disease (COPD).
IPFa COPDb
7.5% (32/428) 2.2% (44/1990)
a From Richeldi L, et al. Efﬁcacy of a tyrosine kinase inhibitor in
idiopathic pulmonary ﬁbrosis. N Engl J Med 2011;365:1079–87.
b From Bateman E, et al. Efﬁcacy and safety of tiotropium Respimat
SMI in COPD in two 1-year randomized studies. Int J Chron
Obstruct Pulmon Dis 2010;5:197–208.clinical trial investigators. Distinguishing between events
related to the disease and those related to the treatment
can be highly demanding in clinical practice. In a cross-
cultural study, it is even more important to deﬁne strict rules
for reporting adverse events. However, weighing the potential
for harm of a new treatment against the potential beneﬁts
may be extremely difﬁcult in a rare and fatal disease with a
variable and unpredictable natural course and a limited
therapeutic armamentarium, such as IPF. As shown in
Table 2, IPF has a much higher incidence of fatal adverse
events compared with COPD. In the global clinical trials of IPF
sponsored by BI, an external independent data monitoring
committee (IDMC) was established to periodically evaluate
the risk–beneﬁt ratio of treatment and to decide whether to
continue or stop the trial prematurely. The IDMC also con-
tinually evaluated the spectrum of adverse effects for early
alarm signs of possible harm during the course of the study,
based on evolving knowledge about the drug. The data ﬂow
and decision tree are shown in Fig. 3.5. Conclusions
For global clinical studies of treatment for rare lung diseases
that are recruiting patients in a variety of trial sites across
countries with different ethnic and cultural backgrounds,
BI has considered it essential to establish a global advisory
board before study registration to reach consensus among
international experts about the diagnosis and management
of the disease. Such expertise is extremely useful to elaborate
a uniform global standard protocol that also considers feasi-
bility issues. The study sites should be selected carefully and
in accordance with the ICH-GCP and sponsor's requirements.
A quality assurance program has to be implemented that
includes training courses for trial staff and a centralized
control system to ensure the uniformity of disease deﬁnition
(diagnostic criteria) and all relevant clinical procedures and
measurements, including a central review of HRCT and/or
biopsy ﬁndings. Finally, an independent data monitoring
committee is a fundamental requirement of global trials to
protect patient rights and safety.
BI has recently completed two large global clinical trials of
nintedanib (INPULSIS™) for the treatment of IPF [10]. Within a
relatively short period, this trial recruited 1066 patients from
study sites in 24 countries across the Americas, Europe, Asia,
and Australia. Careful planning before implementation and
strict management guidelines, including quality control, has: BI
: IDMC
: Primary investigator
ponsored by Boehringer Ingelheim (BI).
r e s p i r a t o r y i n v e s t i g a t i o n 5 3 ( 2 0 1 5 ) 2 – 66meant that this trial has fully complied with the standards
and needs of an international, cross-cultural study.Conﬂict of interest
The author has no conﬂicts of interest.
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